Non-small Cell Lung Cancer Stage III Clinical Trial
Official title:
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish
- the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent
paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with
paclitaxel/carboplatin-based chemotherapy (Phase 1 portion), and
- to assess whether the addition of oral veliparib versus placebo to
paclitaxel/carboplatin-based chemoradiotherapy with paclitaxel/carboplatin consolidation
will improve progression-free survival (PFS) in adults with Stage III non-small cell
lung cancer (Phase 2 portion).
A strategy decision was made not to proceed to Phase 2 portion of this study due to change in
standard of care.
This was to be a 2-phase study consisting of
1. A Phase 1, dose escalation study of veliparib to determine a RPTD for combination with
concurrent paclitaxel/carboplatin-based CRT and paclitaxel/carboplatin-based
consolidation chemotherapy; followed by
2. A Phase 2, randomized, double-blinded study to determine whether veliparib improved
outcome relative to placebo when added to paclitaxel/carboplatin based CRT followed by
consolidation paclitaxel/carboplatin in adults with previously untreated Stage III
NSCLC.
In the dose escalation phase (Phase 1) of the study participants will be assigned to
ascending doses of veliparib in combination with carboplatin, paclitaxel, and thoracic
radiotherapy for 7 weeks following a traditional "3 + 3" design. The first cohort of at least
3 - 6 participants will receive veliparib 60 mg twice a day (BID) throughout CRT. Dose
limiting toxicity (DLT) events will be collected for each dosing cohort until a new dosing
cohort is opened or until the RPTD is identified. Participants will also receive a
consolidation dose of veliparib of 120 mg BID + carboplatin and paclitaxel for up to two
21-day cycles. Once the concurrent CRT RPTD is identified, an additional cohort will be
enrolled to explore the tolerability of a consolidation dose of veliparib at 240 mg BID +
carboplatin + paclitaxel for up to two 21-day cycles.
Following the dose escalation portion of the study, the RPTD will be determined by the
sponsor and the Phase 2 portion of the study will begin with patient randomization in a 1:1:1
ratio to concurrent paclitaxel/carboplatin/radiotherapy/veliparib followed by consolidation
paclitaxel/carboplatin/veliparib, concurrent paclitaxel/carboplatin/radiotherapy/veliparib
followed by consolidation paclitaxel/carboplatin/placebo, or concurrent
paclitaxel/carboplatin/radiotherapy/placebo followed by consolidation
paclitaxel/carboplatin/placebo. Randomization will be stratified by tumor volume (≤ 90 versus
> 90 cm³) and smoking history (current smoker versus former smoker versus never smoked).
Phase 2 was not carried out since during the study there was a change in standard of care for
patients with newly diagnosed, unresectable Stage III NSCLC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05557552 -
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer
|
N/A | |
Active, not recruiting |
NCT04765709 -
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT06449313 -
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06031597 -
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
|
Phase 3 | |
Recruiting |
NCT04728724 -
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT06015815 -
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
|
||
Completed |
NCT03728556 -
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
Completed |
NCT02434081 -
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
Completed |
NCT03550482 -
Oncoxin® and Quality of Life in Cancer Patients
|
Phase 4 | |
Recruiting |
NCT05398094 -
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
|
Phase 2 | |
Completed |
NCT02418234 -
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
|
N/A | |
Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
Not yet recruiting |
NCT05414630 -
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT04941365 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
N/A | |
Not yet recruiting |
NCT06463665 -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)
|
Phase 2 | |
Active, not recruiting |
NCT04699721 -
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC
|
Phase 1 |